• The Journal of Korean Medicine
• /
• v.28 no.2 s.70
• /
• pp.114-125
• /
• 2007

Objectives : Uterine myoma is the most common pelvic benign tumor and may cause abnormal menstrual pattern. The growth of uterine myoma depends on hormones. The 7-zone-diagnostic system (CP-6000A) is a measuring system using skin resistance variability (SRV). The machine shows organic energy and was reported by the gynecologic department to detect functional abnormality of hypothalamus-hypophysis-ovarian axis (H-P-O). Our study was to investigate the SRV of women with uterine myoma by the 7-zone diagnostic system. Methods: Two groups were selected from those who took the CP-6000A test in the College of Korean Medicine Hospital of Sangji University from March 2003 to September 2006. They were divided into normal control (n=40) and uterine myoma groups (n=40). Electrodermal activity of the two groups was compared. Results : The mean value of electrodermal activity of the uterine myoma group was lower than that of thenormal group in all areas on first and second measurement. Especially, the mean value of the patient group was significantly lower than that of the normal group and fell below normal range in the 1, 2, and 3 areas on first and second measurement. Conclusions : The results suggest that women with uterine myoma may have organic energy deficiency and functional abnormality of the H-P-O axis. Further studies to determine the feasibility of this 7 -zone diagnostic system as a reliable diagnostic tool are needed.

• Asian Pacific Journal of Cancer Prevention
• /
• v.14 no.12
• /
• pp.7635-7638
• /
• 2013

Background: Sperm-associated antigen 9 (SPAG9) has been recently proposed as a novel biomarker for early diagnosis of several human tumors, including ovarian, cervical and breast cancers. Its clinical value remains to be clarified for endometrial cancer (EC). In this study, we investigated the utility of serum SPAG9 levels in diagnosis of EC and its association with important clinicopathological parameters. Materials and Methods: This cross-sectional study was performed at a tertiary women's referral center in Ankara, Turkey. Preoperative serum samples were collected from patients surgically treated for endometrial cancer between June 2012-April 2013. Similar aged women with a biopsy proven benign endometrium were used as controls. Serum SPAG9 levels were measured with an enzyme-linked immunosorbent assay (ELISA) method and assessed for links with clinicopathological factors. Receiver operating characteristic (ROC) curve analysis was performed to assess power of SPAG9 levels for EC prediction. P values less than 0.05 were considered statistically significant. Results: A total of 63 women with EC and 27 with benign endometrium were included in the study. Mean age in the EC group was $58.7{\pm}1.1$. Median SPAG9 levels in the EC and control groups were 18.3 (range, 12.7-53.8) and 14.1 (range, 4.3-65.3), respectively (p<0.001). A cut-off value of 17 ng/ml for SPAG9 predicted presence of malignant endometrium with 74% sensitivity and 83% specificity [Area under curve (AUC)=0.82, p<0.001]. SPAG9 levels did not demonstrate any significant association with histological type, FIGO stage, tumor grade, size, myometrial invasion, lymphovascular space invasion, cervical involvement, adnexal involvement, peritoneal cytology or lymph node status (all p>0.05). Conclusions: Testing for SPAG9 may be useful for early detection of EC in asymptomatic high-risk women. Its role in post-treatment follow-up and early detection of recurrence should be assessed in future trials.